High-throughput drug sensitivity detection chip

By designing a cross-combined flow channel structure and valve waste liquid chamber, multiple quantifications and automatic liquid replacement of the high-throughput drug sensitivity detection chip were achieved, solving the problem of low detection efficiency in existing technologies and realizing full-process automation and complex analysis combination of drug sensitivity detection.

CN118002222BActive Publication Date: 2026-11-10HUAZHONG UNIV OF SCI & TECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410081744.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-19
Publication Date
2026-11-10
Estimated Expiration
2044-01-19

AI Technical Summary

Technical Problem

Existing microfluidic drug sensitivity technologies cannot achieve flexible and rapid high-throughput sample formation, nor can they meet the requirement of non-simultaneous mixing of multiple reagents, resulting in low detection efficiency.

Method used

A high-throughput drug sensitivity detection chip is designed, which adopts a cross-combined layout of sample inlet and drug channels. Centrifugal force is used to achieve flexible combination of sample and drug. Valves and waste liquid chambers are set in the chip structure to realize multiple quantification and automatic liquid replacement functions.

Benefits of technology

It improves the efficiency and flexibility of drug susceptibility testing, realizes full-process automation, and can perform complex analytical combinations and injection and quantification of multiple reagents, making it suitable for integrated drug culture and detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118002222B_ABST
    Figure CN118002222B_ABST
Patent Text Reader

Abstract

The application discloses a high-throughput drug sensitivity detection chip, and belongs to the field of micro-fluidic chips, which comprises: detection units arranged around the same centrifugal shaft; the detection unit comprises: a sample inlet flow channel; the sample inlet flow channel comprises one or more sections of connected transverse flow channels; sample quantitative chambers are arranged outside the transverse flow channels, and the transverse flow channels in the same detection unit are sequentially arranged from inside to outside; a drug flow channel; the drug flow channel comprises one or more sections of connected longitudinal flow channels; each section of the longitudinal flow channels intersects with each transverse flow channel, and N drug quantitative chambers are arranged along the longitudinal flow channels, wherein N is the number of the transverse flow channels in the same detection unit; the N drug quantitative chambers correspond to one sample quantitative chamber on the N transverse flow channels respectively, and are located inside the corresponding sample quantitative chambers, and the bottom end is connected with the corresponding sample quantitative chamber through a first micro-channel. The application can realize more flexible and complex analysis combination, and improve the efficiency of drug sensitivity detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of microfluidic chips, and more specifically, relates to a high-throughput drug sensitivity detection chip. Background Technology

[0002] Drug sensitivity testing, used to determine drug sensitivity, provides crucial information for accurate and effective drug therapy. Currently, clinical laboratories primarily use manual serial dilution methods and automated instruments for drug sensitivity testing. Manual serial dilution suffers from low accuracy, cumbersome operation, and long processing time, making it unsuitable for high-throughput drug screening. Automated instruments, on the other hand, are bulky, have complex internal mechanisms, are expensive, and require a large amount of consumables. This necessitates the development of small, integrated instruments.

[0003] Microfluidics, as an emerging scientific technology, has been applied to many fields such as chemistry, biology, engineering, and physics. Its strong interdisciplinary nature has led to breakthroughs in the precise manipulation of time, space, and analytes, enabling the solution of many key problems in life science analysis. Microfluidics can integrate detection experiments that were previously only possible in the laboratory onto a small chip, saving not only consumable costs and time, but more importantly, integrating multiple detection technologies to improve detection efficiency. However, completing a full drug sensitivity reaction generally requires sequentially adding various samples and reagents quantitatively to a reaction tube using a pipette for mixing and reaction, ultimately leading to signal detection. Current microfluidic drug sensitivity technologies mostly focus on single-concentration formation, failing to conveniently and rapidly generate high-throughput samples for drug and drug combination drug sensitivity testing.

[0004] The patent document with patent number ZL2021108258929 discloses a chip for high-throughput reagent quantitative distribution and analysis assisted by microchannels. It successfully realizes the precise injection of quantitative liquids at different radius positions by utilizing hydrophobic extension channels. However, this solution can only realize the quantitative distribution and injection of droplets at different radius positions, and the sample solution and drug solution are only controlled in the lateral dimension, which cannot meet the flexibility requirements of space utilization and multiple reagents not being mixed simultaneously in practical applications. Summary of the Invention

[0005] To address the shortcomings and improvement needs of existing technologies, this invention provides a high-throughput drug sensitivity detection chip. The purpose is to improve the chip structure to achieve more flexible and complex analysis combinations and improve the efficiency of drug sensitivity detection.

[0006] To achieve the above objectives, according to one aspect of the present invention, a high-throughput drug sensitivity detection chip is provided, comprising: one or more detection units arranged around the same centrifugal axis; the detection unit includes:

[0007] At least one sample inlet channel; the sample inlet channel includes one or more transverse channels connected end to end; each sample inlet channel has an inlet at its beginning and is connected to the first waste liquid chamber at its end; a sample quantification chamber is provided outside the transverse channels, and in the same detection unit, all transverse channels are arranged sequentially from the inside to the outside.

[0008] At least one drug flow channel; the drug flow channel includes one or more longitudinal flow channels connected end to end; each drug flow channel has a drug inlet at its first end and is connected to a second waste liquid chamber at its last end; each longitudinal flow channel intersects with each transverse flow channel, and N drug quantitative chambers are arranged along the longitudinal flow channel, where N is the number of transverse flow channels in the same detection unit; each of the N drug quantitative chambers corresponds to a sample quantitative chamber on one of the N transverse flow channels, the drug quantitative chamber is located inside its corresponding sample quantitative chamber, and the bottom of the drug quantitative chamber is connected to its corresponding sample quantitative chamber through a first microchannel.

[0009] Furthermore, the detection unit also includes a third waste liquid chamber that corresponds one-to-one with each sample quantitative chamber; the third waste liquid chamber is located downstream of its corresponding sample quantitative chamber.

[0010] Furthermore, valves are installed on the inner wall of the sample quantitative chamber; the middle of each sample quantitative chamber is connected to the corresponding third waste liquid chamber through a second microchannel.

[0011] Furthermore, the valve is a steam trap, a sacrificial valve, or a soluble membrane valve.

[0012] Furthermore, the detection unit also includes: a fourth waste liquid chamber corresponding to each sample quantitative chamber; each fourth waste liquid chamber is connected to the bottom of the corresponding sample quantitative chamber through a third microchannel, and the connection point between the fourth waste liquid chamber and the third microchannel is lower than the top of the corresponding sample quantitative chamber but higher than the bottom of the corresponding sample quantitative chamber.

[0013] Furthermore, a circular opening is provided at the connection between the fourth waste liquid chamber and the third microchannel.

[0014] Furthermore, the volume of the drug metering chamber on the same drug flow path gradually increases or gradually decreases.

[0015] Furthermore, the detection unit also includes: a buffer storage chamber corresponding to each drug flow channel; the buffer storage chamber is connected to the beginning of the corresponding drug flow channel.

[0016] In summary, the above-described technical solutions conceived in this invention can achieve the following beneficial effects:

[0017] (1) The high-throughput drug susceptibility detection chip provided by the present invention includes horizontally arranged sample inlet channels and vertically arranged drug channels in each detection unit, forming a cross-combination layout. At the same time, sample quantification chambers and drug quantification chambers are provided on the sample inlet channels and drug channels in a one-to-one correspondence and interconnection. Through this channel layout, the present invention can control the combination between samples and drugs in both horizontal and vertical dimensions by means of centrifugation, thereby achieving more flexible and complex analytical combinations. Specifically, the present invention can mix the same sample with different reagents and mix the same reagent with different samples, thereby increasing the analytical throughput and ultimately effectively improving the efficiency of drug susceptibility detection.

[0018] (2) In the preferred embodiment of the high-throughput drug sensitivity detection chip provided by the present invention, a valve is provided on the inner wall of the sample quantitative chamber, and a waste liquid chamber corresponding to each sample quantitative chamber is provided. The sample quantitative chamber and the waste liquid chamber are connected by a microchannel. Since the connection point between the microchannel and the sample quantitative chamber is located in the middle of the sample quantitative chamber, after the sample is quantified by centrifugation, the liquid in the upper part of the sample quantitative chamber can be allowed to flow into the downstream waste liquid chamber through the microchannel by opening the valve to achieve secondary quantification. Centrifugation can be performed again to allow a specified volume of reagent in the drug quantitative chamber to enter the sample quantitative chamber. By repeating the above steps, multiple quantification and automatic liquid exchange of multiple chambers can be achieved. Multiple reagents can be injected and quantified through the same drug flow channel, which provides conditions for the integration of early culture and later drug sensitivity detection, and can realize the full-process automation of drug sensitivity detection.

[0019] (3) In the preferred embodiment of the high-throughput drug sensitivity detection chip provided by the present invention, the bottom end of each sample quantitative chamber is connected to the waste liquid chamber through a microchannel, and the connection point between the microchannel and the waste liquid chamber is lower than the top end of the sample quantitative chamber and higher than the bottom end of the sample quantitative chamber. Thus, after the sample is quantified by centrifugation, the liquid in the sample quantitative chamber can be further centrifuged into the waste liquid chamber. Finally, the liquid level in the sample quantitative chamber will be tangent to the connection point between the microchannel and the waste liquid chamber, thereby realizing secondary quantification. Centrifugation can be performed again to allow a specified volume of reagent in the drug quantitative chamber to enter the sample quantitative chamber. By repeating the above steps, multiple quantification and automatic liquid exchange functions of multiple chambers can be realized. Multiple reagents can be injected and quantified through the same drug flow channel, which provides conditions for the integration of early culture and later drug sensitivity detection, and can realize the full-process automation of drug sensitivity detection. In a further preferred embodiment, a circular opening is provided at the connection between the fourth waste liquid chamber and the third microchannel (i.e., the entrance to the waste liquid chamber). This prevents the liquid from splashing onto the wall during centrifugation and clogging the pores, ensuring that the liquid enters the waste liquid chamber smoothly and accurately completes the secondary quantification.

[0020] (4) In the preferred embodiment of the high-throughput drug sensitivity detection chip provided by the present invention, the volume of the drug quantitative chamber on the same drug flow channel gradually increases or decreases, thereby obtaining reagents with concentration gradients and further realizing more complex analytical combinations.

[0021] (5) In a preferred embodiment of the high-throughput drug sensitivity detection chip provided by the present invention, the detection unit is further provided with a buffer storage chamber connected to the drug flow channel. After the drug is quantified by centrifugation, the buffer is injected into the drug flow channel through the buffer storage chamber. With the assistance of centrifugation, the buffer comes into contact with the reagents in the drug quantification chambers distributed on the drug flow channel in sequence, which will cause the reagent concentration in the drug quantification chambers to gradually increase, thereby obtaining reagents with concentration gradients and further realizing more complex analytical combinations. Attached Figure Description

[0022] Figure 1 This is a schematic diagram of the high-throughput drug sensitivity detection chip provided in Embodiment 1 of the present invention;

[0023] Figure 2 This is a schematic diagram of the structure of each layer in the high-throughput drug sensitivity detection chip provided in Embodiment 2 of the present invention; wherein, (a) is the top cover layer, (b) is the connecting layer, (c) is the reagent layer, (d) is the sample application layer, and (e) is the bottom cover layer;

[0024] Figure 3 This is a schematic diagram of the high-throughput drug sensitivity detection chip provided in Embodiment 2 of the present invention;

[0025] Figure 4 This is a schematic diagram of the high-throughput drug sensitivity detection chip provided in Embodiment 3 of the present invention for secondary quantification; wherein (a), (b), (c), and (d) represent different states in the detection process, respectively;

[0026] Figure 5 This is a schematic diagram of the high-throughput drug sensitivity detection chip provided in Embodiment 4 of the present invention for secondary quantification; wherein (a), (b), (c), (d), and (e) represent different states in the detection process, respectively;

[0027] Figure 6 This is a schematic diagram of the high-throughput drug sensitivity detection chip provided in Embodiment 5 of the present invention for detecting different concentrations; wherein (a), (b), (c), (d), (e), and (f) represent different states in the detection process, respectively;

[0028] In all the accompanying drawings, the same reference numerals are used to denote the same elements or structures, wherein:

[0029] 1-Centrifugal shaft;

[0030] 2-Inlet channel; 21-Transverse channel; 22-Inlet; 23-First waste liquid chamber; 24-Sample quantification chamber;

[0031] 3-Drug flow channel; 31-Longitudinal flow channel; 32-Drug inlet; 33-Second waste liquid chamber; 34-Drug metering chamber;

[0032] 4-First microchannel;

[0033] 5-Third waste liquid chamber;

[0034] 6-Second microchannel;

[0035] 7-Fourth waste liquid chamber;

[0036] 8-Third microchannel. Detailed Implementation

[0037] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention. Furthermore, the technical features involved in the various embodiments of this invention described below can be combined with each other as long as they do not conflict with each other.

[0038] In this invention, the terms "first," "second," etc. (if present), used in the invention and accompanying drawings are used to distinguish similar objects and are not necessarily used to describe a specific order or sequence. Furthermore, in the description of this invention, terms such as "upper," "lower," "left," "right," "inner," and "outer," indicating directional or positional relationships, are based on the directional or positional relationships shown in the accompanying drawings. This is merely for ease of description and does not indicate or imply that the device or element must have a specific orientation, or be constructed and operated in a specific orientation; therefore, it should not be construed as a limitation of this invention. Moreover, it should be noted that in the description of this invention, unless otherwise explicitly specified and limited, the terms "installed," "connected," and "linked" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection of two elements. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.

[0039] It is easy to understand that in centrifugal chips, terms such as "inner side," "outer side," "upstream," "downstream," "high," and "low" are all relative to the distance from the centrifugal axis. Specifically, the side closer to the centrifugal axis is the "inner side," while the side farther from the centrifugal axis is the "outer side." Points closer to the centrifugal axis are located "upstream," while points farther from the centrifugal axis are located "downstream." Points closer to the centrifugal axis are higher points, while points farther from the centrifugal axis are lower points.

[0040] To achieve more complex analytical combinations and improve the efficiency of drug sensitivity detection, this invention provides a high-throughput drug sensitivity detection chip. The overall idea is to improve the chip structure so that the sample inlet channel and drug flow are arranged in a cross-combination layout, thereby achieving more complex analytical combinations.

[0041] The following is an example.

[0042] Example 1:

[0043] A high-throughput drug sensitivity detection chip, such as Figure 1 and Figure 2 As shown, it includes: one or more detection units arranged around the same centrifugal axis 1; the detection unit includes:

[0044] A sample inlet channel 2; the sample inlet channel includes three transverse channels 21, which are connected end to end and arranged sequentially from the inside to the outside, so that the entire sample inlet channel 2 extends in an "S" shape from the near-axis end to the far-axis end; the first end of the sample inlet channel 2 is provided with a sample inlet 22, and the end is connected to the first waste liquid chamber 23; a sample quantification chamber 24 is provided on the outside of the transverse channels;

[0045] Five drug flow channels 3; each drug flow channel 3 includes a longitudinal flow channel 31; each drug flow channel 3 has a drug inlet 32 ​​at its first end and is connected to a second waste liquid chamber 33 at its last end; each longitudinal flow channel 31 intersects with each transverse flow channel 21, and three drug metering chambers 34 are provided along the longitudinal flow channel 31; each of the three drug metering chambers 34 on each longitudinal flow channel 31 corresponds to a sample metering chamber on each of the three transverse flow channels 21; to facilitate the quantitative entry of reagents into the sample metering chamber 24, the drug metering chamber 34 is located inside its corresponding sample metering chamber 24, and the bottom of the drug metering chamber 34 is connected to its corresponding sample metering chamber 24 through a first microchannel 4; optionally, such as Figure 1 and Figure 2 As shown, in this embodiment, each longitudinal flow channel 31 extends from the proximal end to the distal end in a "Z" shape, which facilitates the entry of reagents into the drug quantification chamber 34 during centrifugation.

[0046] In this embodiment, the transverse channels that make up the sample injection channel and the longitudinal channels that make up the drug flow channel are arranged in an intersecting pattern.

[0047] like Figure 1 As shown, in order to create different concentration gradients for the same reagent, in this embodiment, the volumes of the three drug metering chambers on the same drug flow channel gradually decrease, thereby obtaining reagents with gradually decreasing concentrations. In other embodiments of the present invention, the volumes of the drug metering chambers on the same drug flow channel may also gradually increase to obtain gradually increasing reagent concentrations, or the volumes of the drug metering chambers on the same drug flow channel may be set to be the same to achieve repeated measurements of the same reagent concentration.

[0048] Optionally, such as Figure 2 As shown, in this embodiment, the chip has a 5-layer structure, consisting of a top cap layer, a communication layer, a reagent layer, a sample application layer, and a bottom cap layer, from top to bottom. The structure of each layer is as follows: Figure 5 As shown in (a) to (e), where:

[0049] The first microchannel 4, used to connect the sample quantification chamber 24 and the drug quantification chamber 34, is located in the connecting layer;

[0050] The drug flow channel 3 and the drug metering chamber 34 disposed thereon, as well as the second waste liquid chamber 33 connected to the drug flow channel 3, are all located in the reagent layer;

[0051] The sample inlet channel 2 and the sample quantitative chamber 24 set thereon, as well as the first waste liquid chamber 23 connected to the sample inlet channel 2, are all located in the sample loading layer.

[0052] Considering that the Coriolis force and Euler force generated by the high-speed centrifugation process can cause the liquid to deflect, in order to achieve more effective drainage and overcome the influence of the Coriolis force and Euler force on the liquid deflection, as a preferred embodiment, in this embodiment, the first microchannel extends into the sample quantification chamber to which it is connected.

[0053] It should be noted that this is only an optional layered design scheme and should not be construed as the only limitation of the present invention. In other embodiments of the present invention, the number of chip layers and the distribution of each structure in different chip layers may also adopt other design schemes. Under normal circumstances, the sample inlet channel and the drug inlet channel are located in different chip layers.

[0054] The high-throughput drug sensitivity detection chip provided in this embodiment, when applied to drug sensitivity detection in practical applications, follows the following specific detection process:

[0055] S1: Add sample suspension into the sample inlet through the inlet, and push or centrifuge at low speed to guide the sample suspension into the downstream sample quantification chamber. Excess sample solution enters the first waste liquid chamber. Depending on the actual detection requirements, the sample can be primer bacterial solution, cell suspension, cell spheroid suspension or organoid suspension, etc.

[0056] S2: Five different reagents are introduced into each drug flow channel through the inlet of each drug flow channel, or five different concentrations of the same drug can be introduced; the drug solution is guided into the drug flow channel by pushing or low-speed centrifugation. There are three drug metering chambers set on the outside of the drug flow channel to complete the regional introduction of the drug; excess drug solution enters the second waste liquid chamber downstream; it is easy to understand that the centrifugation speed at this time can allow the reagent to enter the drug metering chamber, but it is not enough to break through the microchannel at the bottom of the drug metering chamber.

[0057] S3: After a certain period of time, the liquid in the sample quantitative chamber will gradually evaporate, thus reserving a certain space in the sample quantitative chamber. At this time, under high-speed centrifugation, the drug solution enters the sample chamber through the drainage channel. It is easy to understand that the centrifugation speed at this time can allow the reagent in the drug quantitative chamber to break through the microchannel at the bottom of the drug quantitative chamber and enter the downstream sample quantitative chamber.

[0058] S4: After incubation for a certain period of time, the signal is read.

[0059] It is easy to understand that in this embodiment, when different drugs are introduced into different drug channels, the same sample can be combined with 5 different reagents, and each drug can be combined with 3 different concentrations. Therefore, this embodiment can achieve 15 different combinations. When different concentrations of the same drug are introduced into different drug channels, 15 different concentrations can be achieved after passing through the quantitative chamber. At this time, this embodiment can also achieve 15 different concentration combinations.

[0060] In summary, this embodiment, by designing a flow channel with a crisscross layout, enables more complex analytical combinations, effectively increases detection throughput, and ultimately improves the efficiency of drug sensitivity testing.

[0061] Example 2:

[0062] A high-throughput drug sensitivity detection chip, such as Figure 3 As shown, this embodiment is similar to Embodiment 1 above, except that in this embodiment, there are three sample inlet channels, and each sample inlet channel includes only one transverse channel. The ends of the three sample inlet channels are connected to the same first waste liquid chamber. In some other embodiments of the present invention, when the detection unit is provided with multiple sample inlet channels, each sample inlet channel can also be provided with a separate waste liquid chamber.

[0063] By setting up multiple sample inlet channels, this embodiment can realize the detection of a variety of different samples, increasing the throughput of the detected samples.

[0064] In this embodiment, the specific implementation of the remaining structures can be referred to the description in Embodiment 1 above, and will not be repeated here.

[0065] In practical applications, the reagents introduced through the drug delivery system can also be replaced with bacterial solutions, thereby enabling the study of interactions between bacteria and cells or organoids.

[0066] Example 3:

[0067] A high-throughput drug sensitivity detection chip, such as Figure 4 As shown, this embodiment is similar to Embodiment 1 above, except that in this embodiment, the detection unit further includes:

[0068] The third waste liquid chamber 5 corresponds one-to-one with each sample quantitative chamber 24; the third waste liquid chamber 5 is located downstream of its corresponding sample quantitative chamber 24.

[0069] Furthermore, a high-pass hydrophobic valve is installed on the inner wall of the sample quantitative chamber; the middle of each sample quantitative chamber is connected to the corresponding third waste liquid chamber 5 through the second microchannel 6.

[0070] In this embodiment, after the sample is quantified in the sample solution quantification chamber by centrifugation, the centrifugation is further accelerated. The sample in the sample quantification chamber will be transferred to the bottom of the sample quantification chamber, which will then be filled with supernatant. Furthermore, the supernatant will break through the high-pass hydrophobic valve on the side wall of the sample quantification chamber under centrifugation and be transferred to the downstream third waste liquid chamber, thereby reserving space for the drug to enter and realizing secondary quantification. It is easy to understand that after secondary quantification, the liquid level in the sample quantification chamber will be tangent to the connection point between the second microchannel and the sample quantification chamber.

[0071] A second centrifugation allows the specified volume of reagent in the drug quantification chamber to enter the sample quantification chamber, completing the reaction. The mixing ratio between the sample and reagent can be adjusted by changing the position of the connection point between the second microchannel and the sample quantification chamber.

[0072] In other embodiments of the present invention, the valves installed on the inner wall of the sample quantitative chamber may also be sacrificial valves, soluble membrane valves, or other valves that can control the flow of liquid.

[0073] The high-throughput drug sensitivity detection chip provided in this embodiment can better realize the interaction between samples such as bacterial suspensions or organoids and drugs. For example, the specific detection process is as follows: Figure 4 As shown, the following process can be used:

[0074] S1: Quantification of samples, such as cell suspensions, is performed by low-speed (speed 1) centrifugation. Figure 4 As shown in (a) in the text;

[0075] S2: Under high-speed centrifugation (3000 rpm, rotation speed 2), the cells in the sample are transferred to the bottom of the sample quantification chamber. At this time, the upper layer of the sample quantification chamber is supernatant. Under the action of centrifugal force, the supernatant breaks through the high-pass hydrophobic valve on the side wall of the sample quantification chamber and is transferred to the downstream waste liquid chamber, realizing secondary quantification. Figure 4 As shown in (b) in the image;

[0076] S3: Quantify the drug by low-speed (speed 1) centrifugation, such as... Figure 4 As shown in (c);

[0077] S4: Increase the rotation speed to between speeds 1 and 2, such as 1500 rpm, so that a fixed amount of drug enters the sample chamber. Figure 4 As shown in (d) in the figure.

[0078] Example 4:

[0079] A high-throughput drug sensitivity detection chip, such as Figure 5 As shown, this embodiment is similar to the above embodiment 1, except that in this embodiment, the detection unit further includes: a fourth waste liquid chamber 7 corresponding to each sample quantitative chamber 24; each fourth waste liquid chamber 7 is connected to the bottom end of the corresponding sample quantitative chamber 24 through a third microchannel 8, and the connection point between the fourth waste liquid chamber 7 and the third microchannel 8 is lower than the top end of the corresponding sample quantitative chamber 24 and higher than the bottom end of the corresponding sample quantitative chamber 24.

[0080] In this embodiment, after quantifying the sample by centrifugation, further centrifugation is used to transfer the liquid from the sample quantification chamber into the waste liquid chamber. Finally, the liquid level in the sample quantification chamber will be tangent to the connection point between the microchannel and the waste liquid chamber, achieving secondary quantification. Centrifugation again allows a specified volume of reagent from the drug quantification chamber to enter the sample quantification chamber, completing the mixing and reaction. In this embodiment, the mixing ratio between the sample and reagent can be adjusted by adjusting the height of the fourth waste liquid chamber or the height of the connection point between the third microchannel and the fourth waste liquid chamber.

[0081] By repeating the above steps, multiple quantitative measurements and automatic liquid exchange in multiple chambers can be achieved. Multiple reagents can be injected and quantified through the same drug flow channel, thereby better realizing the step-by-step addition and mixing of drugs, the integration of drug sensitivity and detection, and the integration of drug sensitivity and culture.

[0082] In practical applications, the volume of the fourth waste liquid chamber can be determined according to the volume of liquid that needs to be removed during the entire detection process. To facilitate multiple liquid changes, in this embodiment, the volume of the fourth waste liquid chamber is much larger than the volume of the sample quantification chamber. For example... Figure 5As shown in this embodiment, a circular opening is provided at the connection between the fourth waste liquid chamber and the third microchannel, i.e., at the entrance of the fourth waste liquid chamber. This prevents the liquid from splashing onto the upper wall during centrifugation and clogging the pores, ensuring that the liquid enters the waste liquid chamber smoothly and accurately completes the secondary quantification.

[0083] When this embodiment is used for detection, the specific detection process is as follows: Figure 5 As shown, the following process can be used:

[0084] S1: Samples, such as cell suspensions, are propelled into the sample quantification chamber via a push or low-speed centrifugation channel, achieving single-step quantification. Due to the small volume and high resistance of the microchannel, and the larger volume of the waste liquid chamber compared to the sample quantification chamber, the communicating vessel effect is avoided, and the sample is stored in the sample quantification chamber. Figure 5 As shown in (a) in the text;

[0085] S2: During high-speed centrifugation (2500 rpm), excess liquid in the sample quantification chamber enters the waste liquid chamber under centrifugal force. The waste liquid chamber has vents at the top, with the vent height higher than the sample inlet channel, thus expelling gas from the fourth waste liquid chamber and allowing liquid to smoothly enter. This ensures that the liquid level in the sample quantification chamber is tangent to the bottom of the waste liquid chamber inlet after high-speed centrifugation, achieving secondary quantification. Figure 5 As shown in (b) in the image;

[0086] S3: The drug is quantified by pushing or low-speed centrifugation through the drug flow channel into the drug metering chamber. Figure 5 As shown in (c);

[0087] S4: Centrifuge again at high speed (2000 rpm) to ensure that a quantified amount of drug enters the sample quantification chamber. Figure 5 As shown in (d), simultaneously, after the drug solution is mixed with the sample, the excess liquid re-enters the waste liquid chamber, completing three quantitative measurements, as shown in the figure. Figure 5 (e) in the middle.

[0088] Repeating the S3-S4 process allows for a gradual decrease in the concentration of the same drug or a sequential combination of different drugs. It also makes it easier to detect sample activity or add other reagents, thus integrating drug sensitivity testing with detection.

[0089] It should be noted that by adjusting the height of the waste liquid chamber to perform secondary quantification of different volumes in the sample quantification chamber, and then manually injecting the sample again after centrifugation, automatic liquid exchange of multiple chambers can be achieved, which provides conditions for the integration of early culture and later drug sensitivity testing.

[0090] Example 5:

[0091] A high-throughput drug sensitivity detection chip, such as Figure 6As shown, this embodiment is similar to embodiment 4 above, except that in this embodiment, the detection unit includes only one sample inlet channel and one drug inlet channel. The sample inlet channel includes three transverse channels connected end to end, and the drug inlet channel includes five longitudinal channels connected end to end. In this embodiment, the detection unit also includes:

[0092] A buffer storage chamber (not shown in the figure) corresponds to the drug flow channel and is connected to the beginning of the corresponding drug flow channel. A certain volume of buffer solution can be pre-stored in the buffer storage chamber. When using the chip for detection, after reagent quantification is completed, the buffer solution in the buffer storage chamber is released and centrifuged, so that the buffer solution comes into contact with the reagent in the drug quantification chamber in sequence. This causes the reagent concentration in the drug quantification chamber to increase sequentially from front to back, thereby achieving a higher throughput concentration gradient of the drug in the tank and enabling multiple quantifications.

[0093] It is easy to understand that the buffer solution is a liquid that does not affect the properties of the reagent. Optionally, in this embodiment, the buffer solution used is an isotonic solution of the cell suspension to be tested.

[0094] When the high-throughput drug sensitivity detection chip provided in this embodiment is used for detection, the following procedure can be followed:

[0095] S1: The sample solution, such as a cell suspension, is first quantified by pushing or low-speed centrifugation, such as... Figure 6 As shown in (a) in the text;

[0096] S2: During high-speed centrifugation (2500 rpm), a portion of the sample solution is transferred to the waste liquid chamber to reserve space for subsequent drug entry. At this point, the liquid level is tangent to the bottom of the waste liquid chamber inlet, completing the second quantification. Figure 6 As shown in (b) in the image;

[0097] S3: A third quantification of the drug is performed by pushing or low-speed centrifugation, such as... Figure 6 As shown in (c);

[0098] S4: Introduce the buffer solution (e.g., 100 μL) stored in the buffer storage chamber into the beginning of the drug flow channel, and inject air at a fixed flow rate to propel the liquid through the drug flow channel. During the contact between the buffer solution and each drug metering chamber, a certain amount of solution exchange occurs, resulting in a decrease in the liquid concentration in the metering chamber and an increase in the drug concentration in the buffer solution. As the buffer solution flows sequentially to the next chamber, the drug concentration gradient within the metering chamber increases sequentially from front to back. Figure 6 As shown in (d) and (e);

[0099] S5: Under high-speed centrifugation (2500 rpm), the drug solution enters the metering chamber, and excess liquid enters the waste liquid chamber through a microchannel. Finally, the liquid level in the metering chamber reaches tangent to the bottom of the waste liquid chamber inlet, completing the fourth metering step. Figure 6 As shown in (f) in the figure.

[0100] Similarly, the S2-S4 operations can be repeated to achieve the mixing and quantification of multiple drugs at multiple gradients.

[0101] It should be noted that in some other embodiments of the present invention, such as in embodiment 4, a separate buffer storage chamber may not be provided. Instead, after the reagent quantification is completed, the buffer is directly introduced from the drug inlet. That is to say, in step S4 above, a certain volume of buffer (e.g., 100 μL) is directly added to the inlet of the drug flow channel, instead of introducing the buffer stored in the buffer storage chamber (e.g., 100 μL) into the beginning of the drug flow channel. The remaining steps are the same.

[0102] Those skilled in the art will readily understand that the above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A high-throughput drug sensitivity detection chip, characterized in that, include: One or more detection units arranged around the same centrifugal axis; the detection unit includes: At least one sample inlet channel; the sample inlet channel includes a transverse channel or a channel formed by connecting multiple transverse channels end to end, extending from the proximal end in an "S" shape to the distal end; each sample inlet channel has an inlet at its beginning and is connected to a first waste liquid chamber at its end; a sample quantification chamber is provided outside the transverse channel, and in the same detection unit, all transverse channels are arranged sequentially from the inside to the outside; At least one drug flow channel; the drug flow channel includes a longitudinal flow channel extending in a "Z" shape from the proximal end to the distal end; each drug flow channel has a drug inlet at its first end and is connected to a second waste liquid chamber at its last end; the longitudinal flow channel intersects with each transverse flow channel, and N drug quantitative chambers are arranged along the longitudinal flow channel, where N is the number of transverse flow channels in the same detection unit; each of the N drug quantitative chambers corresponds to a sample quantitative chamber on one of the N transverse flow channels, the drug quantitative chamber is located inside its corresponding sample quantitative chamber, and the bottom end of the drug quantitative chamber is connected to its corresponding sample quantitative chamber through a first microchannel; A third or fourth waste liquid chamber that corresponds one-to-one with each sample quantitative chamber; The third waste liquid chamber is located downstream of its corresponding sample quantitative chamber; and the inner wall of the sample quantitative chamber is also equipped with a valve; the middle of each sample quantitative chamber is connected to the corresponding third waste liquid chamber through a second microchannel; Each fourth waste liquid chamber is connected to the bottom of the corresponding sample quantitative chamber via a third microchannel, and the connection point between the fourth waste liquid chamber and the third microchannel is lower than the top of the corresponding sample quantitative chamber but higher than the bottom of the corresponding sample quantitative chamber.

2. The high-throughput drug sensitivity detection chip as described in claim 1, characterized in that, The valve is a steam trap, a sacrificial valve, or a soluble membrane valve.

3. The high-throughput drug sensitivity detection chip as described in claim 1, characterized in that, A circular opening is provided at the connection between the fourth waste liquid chamber and the third microchannel.

4. The high-throughput drug sensitivity detection chip according to any one of claims 1 to 3, characterized in that, The volume of the drug metering chamber on the same longitudinal flow channel gradually increases or gradually decreases.

5. The high-throughput drug sensitivity detection chip according to any one of claims 1 to 3, characterized in that, The detection unit also includes a buffer storage chamber corresponding to each drug flow channel; the buffer storage chamber is connected to the beginning of the corresponding drug flow channel.

Citation Information

Patent Citations

  • Micro-fluidic chip with multi-layer modular concentration gradient formation structure

    CN116371490A